Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?

• Published in: International Urogynecology Journal 2021-05, Vol.32 (5), p.1117-1127
• Main Authors: Wu, Jia-Pei, Peng, Liao, Zeng, Xiao, Li, Hao, Shen, Hong, Luo, De-Yi
• Format: Article
• Language: English
• Subjects: Bias; Bladder; Clinical trials; Constipation; Drugs; Gynecology; Humans; Imidazoles; Medicine; Medicine & Public Health; Mouth; Muscarinic Antagonists; Nocturia; Performance evaluation; Pharmaceutical Preparations; Quality of life; Review Article; Treatment Outcome; Urinary Bladder, Overactive; Urology
• ISSN: 0937-3462; 1433-3023
• DOI: 10.1007/s00192-020-04329-x

Purpose Previous studies have included a limited number of randomized controlled trials (RCTs) and compared limited parameters after treatment with imidafenacin and other anticholinergic drugs (ADs) for overactive bladder syndrome (OAB), and controversy about the superiority of these ADs still remains. We aim to update the evidence and provide better clinical guidance. Methods A systematic search of PubMed, Embase, ClinicalTrial.gov and Cochrane Library Central Register of Controlled Trials was conducted from January 2007 to April 2019. Meta-analysis of all published RCTs comparing imidafenacin with other ADs in patients with OAB was performed. The primary outcomes were the changes in OAB symptoms and OAB symptom score (OABSS). Secondary outcomes included adverse events (AEs) and the dropout rate related to AEs. Results A total of 6 studies including 7 RCTs involving 1430 patients with mean follow-up of 23.43 weeks were included. All ADs improved OAB symptoms. Regarding efficacy, these drugs had similar efficacy in voids, urgency episodes, urgency incontinence episodes, incontinence episodes and OABSS. However, imidafenacin performed better in the reduction of nocturia episodes (MD = –0.24, 95% CI –0.44 to –0.04, P  = 0.02). Moreover, imidafenacin was associated with a statistically lower dry mouth rate (RR = 0.87, 95% CI 0.75–1.00, P  = 0.04), lower constipation rate (RR = 0.68, 95% CI 0.50–0.93, P  = 0.01) and lower AE-related withdrawal rate (RR = 0.51, 95% CI 0.29–0.89, P  = 0.02). There was no significant difference in terms of other complications. Conclusions In conclusion, imidafenacin was comparable to other ADs in the treatment of OAB. Moreover, imidafenacin presented a lower dry mouth rate, lower constipation rate and higher adherence and persistence.